Stocks trading below cash value on the NAS February 2026

February 06, 2026

Below Cash Value

Companies are trading below cash value when their current share price is less than the cash per share on their balance sheet or with more cash than market cap. Companies can have more cash per share than the actual share price for a number of reasons, including that they just raised capital, are in industries that experience high burn rates, or there is a lot of uncertainty about the future of the company.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

About the Data

This table includes companies whose current share price is less than the cash per share on their balance sheet or stocks with more cash than market cap. We also include the value of cash net debt per share to show how much cash per share would be left if the debt was paid off.

How do you use this table?

Stocks on this list have potential for higher reward and risk. It is imperative to understand why these companies are trading at less than cash value. Stocks in this category are generally held for speculation or growth.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

Symbol Name Close Price Shares Outstanding P/E P/B Cash per Share Net Cash per Share
BCYC Bicycle Therapeutics Ltd 6.00 49929952 - 0.8 15.88 15.70
AMCX AMC Networks Inc 7.73 32042361 - 0.4 27.16 -48.37
ARCT Arcturus Therapeutics Holdings Inc 7.32 28412537 - 1.0 7.64 6.13
BRLT Brilliant Earth Group Inc 1.56 15170213 - 2.5 9.71 3.22
BTM Bitcoin Depot Inc. 0.97 35360672 8.9 5.6 0.99 -0.78
ALGS Aligos Therapeutics Inc 7.52 5353582 - 1.0 13.78 12.31
BCAB Bioatla Inc 0.19 58792088 - 2.7 0.55 0.54
BIRD Allbirds Inc 3.56 5670752 - 0.7 6.89 -0.81
BRNS Barinthus Biotherapeutics plc 0.74 40830353 - 0.3 2.43 2.14
ALLR Allarity Therapeutics Inc 0.89 14524080 0.2 1.5 1.74 1.64
All data provided as at market close February 02, 2026.

Company Details

Bicycle Therapeutics Ltd

BCYC:NAS

Shares Outstanding

49929952

Cash per Share

15.88

Net Cash per Share

15.70

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.

Access the stockcalc valuation


AMC Networks Inc

AMCX:NAS

Shares Outstanding

32042361

Cash per Share

27.16

Net Cash per Share

-48.37

AMC Networks Inc., an entertainment company, distributes contents in the United States, Europe, and internationally. The company operates through two segments Domestic Operations and International.

Access the stockcalc valuation


Arcturus Therapeutics Holdings Inc

ARCT:NAS

Shares Outstanding

28412537

Cash per Share

7.64

Net Cash per Share

6.13

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA.

Access the stockcalc valuation


Brilliant Earth Group Inc

BRLT:NAS

Shares Outstanding

15170213

Cash per Share

9.71

Net Cash per Share

3.22

Brilliant Earth Group, Inc. designs, procures, and sells diamonds, gemstones, and jewelry in the United States and internationally. The company offers diamond engagement rings, wedding and anniversary rings, gemstone rings, and fine jewelry. It sells directly to consumers through its omnichannel sales platform, e-commerce, and showrooms. Brilliant Earth Group, Inc. was founded in 2005 and is based in San Francisco, California.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Bitcoin Depot Inc.

BTM:NAS

Shares Outstanding

35360672

Cash per Share

0.99

Net Cash per Share

-0.78

Bitcoin Depot Inc. owns and operates a network of bitcoin ATMs in North America and Hong Kong. Its customers can buy and sell bitcoin through its kiosks in various retail locations, such as convenience stores and gas station chains; pharmacies and grocers; and mall operators. The company also sells cryptocurrency to consumers at a network of retail locations through its BDCheckout product offering, as well as its website. The company was founded in 2016 and is headquartered in Atlanta, Georgia.

Access the stockcalc valuation


Aligos Therapeutics Inc

ALGS:NAS

Shares Outstanding

5353582

Cash per Share

13.78

Net Cash per Share

12.31

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

Access the stockcalc valuation


Bioatla Inc

BCAB:NAS

Shares Outstanding

58792088

Cash per Share

0.55

Net Cash per Share

0.54

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

Access the stockcalc valuation


Allbirds Inc

BIRD:NAS

Shares Outstanding

5670752

Cash per Share

6.89

Net Cash per Share

-0.81

Allbirds, Inc. manufactures and sells footwear and apparel products for men and women in the United States and internationally. The company offers a range of lifestyle products; shoes; and apparel, including classic tees and sweats, socks, and underwear. It sells its products through its retail stores, and third-party retailers and distributors, as well as digital channels comprising websites and marketplace platforms. The company was formerly known as Bozz, Inc.

Access the stockcalc valuation


Barinthus Biotherapeutics plc

BRNS:NAS

Shares Outstanding

40830353

Cash per Share

2.43

Net Cash per Share

2.14

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease.

Access the stockcalc valuation


Allarity Therapeutics Inc

ALLR:NAS

Shares Outstanding

14524080

Cash per Share

1.74

Net Cash per Share

1.64

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Bicycle Therapeutics and AMC Networks on the NAS were trading below cash value this month. See the full list of companies trading below cash on the blog: https://www.stockcalc.com/Blog/stocks-trading-below-cash-value-nas-february-2026
Bicycle Therapeutics $BCYC and AMC Networks $AMCX were trading below cash value on the #NAS this month. See the full list of companies trading below cash: https://www.stockcalc.com/Blog/stocks-trading-below-cash-value-nas-february-2026
Bicycle Therapeutics and AMC Networks on the NAS were trading below cash value this month. See the full list of companies trading below cash on the blog: https://www.stockcalc.com/Blog/stocks-trading-below-cash-value-nas-february-2026

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.